November 05, 2010 (BiotechBlog) PruGen IP Holdings, Inc. awarded a grant under the U.S. Government's Qualifying Therapeutic Discovery Program.

PruGen IP Holdings, Inc. is a pharmaceutical product research & development, acquisition, and licensing company specializing in generic and novel prescription drug applications.  This includes our Patent Pending Drug Delivery Technology, "DBEDS". PruGen offers this technology in conjunction with its drug development services. Founded in 2008, PruGen IP Holdings, Inc. currently holds the rights to 11 trademarks and four 510k cleared products for which it has entered into revenue producing license agreements.  The Company filed an ANDA in the second quarter of 2010 and will file a second ANDA application in the fourth quarter of 2010.

Currently, PruGen IP Holdings, Inc. owns the rights to 15 innovative pharmaceutical formulations, six of which have current US and PCT patent applications pending.  Patent applications for the remaining products will be filed in late 2010 and early 2011.  All 15 formulations are in active stages of development including R&D, human clinical studies, FDA filings, or final commercial development. 

The Company seeks prescription drug products and partners interested in co-development, licensing or sale of novel prescription drug formulations or ANDA registrations.

Current PruGen IP Holdings, Inc. proprietary product partner opportunities include the following areas:

  1. Onychomycosis
  2. Tinea pedis
  3. Acne
  4. Drug delivery
  5. Seborrheic Dermatitis
  6. Hypertriglyceridemia
  7. Atopic Dermatitis
  8. Rosacea

If you or your company have an interest in speaking with PruGen IP Holdings, Inc., please see our "Contact Us" page